Sunshine Biopharma to Execute One-for-Ten Reverse Split, Cutting Shares to 2.12M
SBFM•Sunshine Biopharma Inc. will implement a one-for-ten reverse stock split when markets open on June 1, 2026 to regain compliance with NASDAQ's minimum bid price requirement. The action will reduce outstanding shares from 21,236,346 to approximately 2,123,635, concentrating the float and potentially boosting per-share value.
1. Reverse Stock Split Details
Sunshine Biopharma will implement a one-for-ten reverse split of its common stock at market open on June 1, 2026, consolidating every ten shares into one to adjust its share count.
2. Nasdaq Compliance Rationale
The reverse split aims to lift the company's share price above the required minimum bid level for NASDAQ, preventing delisting due to low per-share valuations.
3. Share Count Reduction and Operations
Prior to the split, the company had 21,236,346 shares outstanding, which will be reduced to approximately 2,123,635. Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, has 12 additional launches slated for 2026, and is developing two novel therapeutics targeting liver cancer and SARS coronavirus infections.
